CN109666743B - A kind of cervical carcinoma molecular marker and its application - Google Patents
A kind of cervical carcinoma molecular marker and its application Download PDFInfo
- Publication number
- CN109666743B CN109666743B CN201910100360.1A CN201910100360A CN109666743B CN 109666743 B CN109666743 B CN 109666743B CN 201910100360 A CN201910100360 A CN 201910100360A CN 109666743 B CN109666743 B CN 109666743B
- Authority
- CN
- China
- Prior art keywords
- hsa
- circ
- cervical
- application according
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of cervical carcinoma molecular marker and its applications, and in particular to the application of hsa_circ_0020594 and its related gene hsa-let-7c-5p in diagnosing cervical.Inventor is further excavated to cervical carcinoma sequencing data and confluence analysis, search out the key molecule hsa_circ_0020594 and its related gene hsa-let-7c-5p for participating in regulation cervical carcinoma, and biological information regulated and control network is drawn, new molecular diagnostic markers are provided for the diagnosis of cervical squamous cell carcinoma.
Description
Technical field
The invention belongs to oncogene detection technique fields, and in particular to the relevant circRNA molecular marker of cervical carcinoma
And its application in diagnostic reagent is being prepared, more particularly relate to hsa_circ_0020594 and its related gene hsa-let-
Application of the 7c-5p in diagnosing cervical.
Background technique
Cervical carcinoma is one of big reproductive system malignant tumour of women three, seriously threatens women's health.Early clinic symptom is not
Obviously, and the main method made a definite diagnosis --- pathological tissue biopsy has invasive.The generally acknowledged reliable molecule mark of cervical carcinoma at present
Will object includes DNA, RNA, protein three categories.In recent years, scholars have found more and more RNA class molecular markers in cervical carcinoma
Middle unconventionality expression has close relationship with clinical pathologic characteristic, transfer and the invasion of cervical carcinoma etc..LncRNA,miRNA,
CircRNA not coding proteins, by before transcription, transcription and post-transcriptional level directly or indirectly regulate and control encoding gene, from
And influence the generation of the expression of target gene, tumour.The research of RNAs and cervical carcinoma has good development prospect, can be used as uterine neck
Cancer auxiliary diagnosis, the biomarker for judging curative effect, assessing prognosis can also provide new target direction for treatment.
Circular rna (circular RNA, circRNA)) it is the novel non-coding RNA that a kind of structure is different from linear rna,
It is the special cyclic structure being made of 3 ' ends and 5 ' end reverse splicings, covalent bond.CircRNA is after lncRNA, miRNA
Another emerging star of RNA family later, special cyclic structure, biological function cause extensive concern and the research of scholars.
It has now been found that circRNA has by the progress for the regulation disease that interacts to related miRNA, mRNA as novel clinical
Diagnose the potentiality of molecular marker.The function of circRNA is mainly manifested in following several: (1) serving as the effect of miRNA sponge；(2)
The effect of controlling gene transcriptional expression；(3) it interacts, participates in rna binding protein (RNA binding protein, RBP)
The expression of RNA or protein play the regulating and controlling effect etc. to target gene.
The extensive use of high throughput sequencing technologies provides for the research of disease pathogenesis more to divide comprehensively and quickly
Analysis means, inventor is further excavated to cervical carcinoma sequencing data and confluence analysis, is constructed with bioinformatics method
The biological information regulated and control network of circRNA-miRNA-mRNA interaction, by GeneCoDis3 in biological information network
The target gene of miRNA and the derived genes of circRNA carry out GO functional analysis and Pathway analysis respectively, find and participate in adjusting
Control the key molecule of cervical carcinoma, it was found that hsa_circ_0020594.Currently, not researches show that hsa_circ_0020594 with
Whether cervical carcinoma is related, and also further analysis obtains the hsa-let-7c- to interact with hsa_circ_0020594 to inventor
The target gene of 5p and hsa-let-7c-5p constructs hsa_circ_0020594 biological information regulated and control network.The application is
The diagnosis of cervical carcinoma provides new molecular diagnostic markers, provides Research foundation for clinical disease genetic test.
Summary of the invention
The purpose of the present invention is to provide the reagents of detection hsa_circ_0020594 and/or its related gene in preparation palace
Application in neck cancer diagnostic preparation, sequence and SEQ ID NO.1 have 90% or more sequence homology.
Term " homologous " be primarily referred to as it is homologous in sequence, that is, be used to illustrate two or more RNA or DNA sequence dna
Ancestors having the same.Homologous sequence generally has similar function.In general, it when similarity degree is higher than 50%, often pushes away
It surveys detection sequence and target sequence may be homologous sequence；When degree of similarity is lower than 20%, just it is difficult to determine if having
There is homology.
Preferably, sequence and SEQ ID NO.1 have 95%, 96%, 97%, 98% or 99% or more sequence homology.
Preferably, sequence and SEQ ID NO.1 have 95% or more sequence homology.
It is furthermore preferred that sequence is SEQ ID NO.1.
Preferably, related gene is the target of hsa-let-7c-5p (sequence is SEQ ID NO.2) or hsa-let-7c-5p
Gene.
Further, the target gene of hsa-let-7c-5p is selected from one of the following or several: IGF2BP2, POLQ,
IFI44L、CHEK1、COL4A1、DNA2、ELAVL1、SENP5、EZH2、USP12、TMEM2、BACE2、ZNF473、GALNT2、
AHCTF1、OSBPL3、RPUSD2、C19orf54、HOXC11、CXCL8、GOLT1B、HSPA14、TAF9B、CCDC93、DARS2、
IPO9、UGGT1、POGLUT1、BBX、RAD1、RRM2、DCLRE1B、SLC20A1、AURKA、TAF5、TAZ、TFDP2、TK1、
TRAPPC10、TMPO、ZNF79、ZNF200、PXDN、TSEN34、EIF2S2、CCNF、H2AFV、CDC25A、SUPT16H、
CTPS1、DHX9、DNA2、DNMT1、EZH2、ARL6IP1、ACOT9、GABPB1、TMEM184B、RBM12B、LYN、MICB、
RFWD3、FANCI、PRIM2、IPO9、PSMB2、RRM2、SLC20A1、TAF5、TAZ、TTF1、ZNF200、TRRAP、CCNF、
BAZ1B, CCNB2, NUP155, CEP135 or KIAA0391.
Preferably, the target gene of hsa-let-7c-5p is CCNB2.
Further, reagent detects sample hsa_circ_ using sequencing technologies, nucleic acid hybridization technique or nucleic acid amplification technologies
The expression of 0020594 and/or its related gene.
Nucleic acid hybridization technique in the present invention includes but is not limited in situ hybridization (ISH), microarray or Northern hybridization.
Preferably, using high throughput sequencing technologies, probe hybridization technique, biochip technology or fluorescent quantitative PCR technique
Detect the expression of hsa_circ_0020594 and/or its related gene in sample.
Preferably, reagent contains the probe hybridized with hsa_circ_0020594 or expands the spy of hsa_circ_0020594
Specific primer.
Preferably, primer sequence is SEQ ID NO.3 and SEQ ID NO.4.
Preferably, sample is cervical cancer tissues or peripheral blood.
It is furthermore preferred that cervical carcinoma is cervical squamous cell carcinoma.
A kind of cervical carcinoma detection PCR kit for fluorescence quantitative, the kit are drawn using special upstream primer and downstream
The expression of analyte detection hsa_circ_0020594 and/or its related gene.
Preferably, related gene is the target gene of hsa-let-7c-5p or hsa-let-7c-5p.
Further, which is suitable for presently, there are all types fluorescence quantitative gene extender in the market, clever
Sensitivity is high, it is quantitative quick and precisely, stability it is good, have a good application prospect.
Further, above-mentioned PCR kit for fluorescence quantitative component includes: specific primer, internal control primer, quantitative fluorescent PCR
Reaction solution.Wherein the specific primer includes upstream primer and downstream primer, and upstream primer sequence is SEQ ID NO.3,
Downstream primer sequence is SEQ ID NO.4.The internal control primer is GAPDH internal control primer.
The kit also includes RNA extraction agent.It is preferred thatReagent carries out sample rna extraction.
The advantages of the application:
1, the application confirms that hsa_circ_0020594 can be used as the diagnosis marker of cervical squamous cell carcinoma, hsa_ for the first time
Circ_0020594 expression quantity in cervical squamous cell cancer is higher than cancer beside organism, shows that hsa_circ_0020594 can be used as uterine neck
The diagnosis marker of squamous carcinoma；
2, detection discovery hsa_circ_0020594 specificity overexpression in cervical squamous cell carcinoma, Detection accuracy is higher, mentions
A kind of more fast and accurately detection method is supplied；
3, the application provides new molecular diagnostic markers for the diagnosis of cervical squamous cell carcinoma.
Definition:
Circular rna (circular RNA, circRNA), also known as annular RNA are a kind of new of research confirmation recent years
Non-coding RNA (noncoding RNA, ncRNA) molecule of type.According to the difference that RNA is constituted, circular rna can be divided into three classes: outer
Show sub- circular rna (exon circular RNA, ecircRNA), introne circular rna (circular intronic RNAs,
) and exon: intron circRNA (exon-intron circRNA, EIciRNA) ciRNAs.
" probe " refers to can be with the molecule in conjunction with the particular sequence of another molecule or subsequence or other parts.Unless otherwise finger
Out, term " probe " is often referred to that the polynucleotide probes in conjunction with another polynucleotides can be matched by complementary base.
The probe has the base sequence with the specific base sequence complementary of target gene.Here, so-called " complementation ",
As long as hybridization, can not be complete complementary.These polynucleotides have usually relative to the specific base sequence
80% or more, preferably 90% or more, more preferable 95% or more, particularly preferred 100% homology.These probes can be DNA,
It is also possible to RNA, furthermore it is possible to pass through PNA (Polyamide nucleic in part of it or whole nucleotides
Acid, peptide nucleic acid), LNA (registered trademark, locked nucleic acid, Bridged Nucleic Acid, Cross-linked core
Acid), ENA (registered trademark, 2 '-O, 4 '-C-Ethylene-bridged nucleic acids), GNA (Glycerol
Nucleic acid, glycerol nucleic acid), the artificial replacement nucleic acid such as TNA (Threose nucleic acid, threose nucleic acid) obtains
Polynucleotides.Term " hybridization " in the present invention is used to refer to the pairing of complementary nucleic acid.Hybridization and intensity for hybridization are by such as following
Factor influence: in the stringency of complementarity, related condition between nucleic acid, the Tm and nucleic acid of the hybrid of formation
G:C ratio.
Sequencing technologies are mainly high throughput sequencing technologies (High-throughput sequencing), also known as next-generation to survey
Sequence technology (next generation sequencing) once carries out sequencing to millions of DNA moleculars to hundreds of thousands,
Greatly improve sequencing efficiency.The representative of high-flux sequence platform is 454 sequenator (Roch of Roche Holding Ag (Roche)
GSFLX sequencer), the Solexa genome analysis instrument (Illumina Genome Analyzer) of Illumina company and
The SOLiD sequenator (ABI SOLiD sequencer) of ABI.Northern hybridization, also known as Northern blot are most classic
Eucaryote RNA size is detected, estimates the experimental method of its abundance.Basic principle is as follows: first in carrier (such as silicon wafer, microballoon
Or film etc.) on fix RNA sample, then hybridize with the probe by label, carry out signal detection after washing extra hybridization probe；
The DNA probe complementary with target RNA sequence can also be first fixed on carrier, then hybridized with the sample rna by label, then into
Row signal detection.The method of signal label includes isotope labelling, fluorescent marker and nano gold mark etc..
Detailed description of the invention
Fig. 1 is hsa_circ_0020594-miRNA-mRNA interaction network figure
Fig. 2 is hsa_circ_0020594 differential expression figure in cervical squamous cell carcinoma and cancer beside organism
Specific embodiment
Present invention will be further explained below with reference to specific examples, for explaining only the invention, and should not be understood as to this
The limitation of invention.It will be understood by those skilled in the art that: without departing from the principle and spirit of the present invention may be used
To carry out a variety of change, modification, replacement and modification to these embodiments, the scope of the present invention is limited by claim and its equivalent
It is fixed.In the following examples, the experimental methods for specific conditions are not specified, usually according to normal condition or according to item proposed by manufacturer
Part examinations.
1 data screening of embodiment and confluence analysis
GEO (Gene Expression Omnibus) database is by NCBI (US National Biotechnology Information center)
Exploitation maintenance, database of the GEO database as maximum gene expression data.It formulates data set and is included in standard:
1. selected data collection is necessary for the mRNA/miRNA/circRNA transcript profile data of full-length genome；
2. these data from cervical squamous cell carcinoma (CSCC) case group and control group (N) tissue (no medicine irritation or by
Transfection)；
3. this research considers normalized or raw data set.
It is screened, obtains following data collection:
Table 1 screens the data set list being included in
Data analysis:
The use of tool is R-3.3.3, is analyzed using metaMA packet, it is inverse that p value, which merges method therefor, in meta analysis
normal method。
Differential expression mRNA screening criteria: FDR<0.05, | combined.ES |>1；And it is different by being lowered on each data set
The mRNA of cause casts out, and obtains 1356 differential expression mRNA altogether；
Differential expression miRNA screening criteria: FDR<0.05, | combined.ES |>1；And it is different by being lowered on each data set
The miRNA of cause casts out, and obtains 13 differential expression miRNA altogether.
It is analyzed using limma packet.Differential expression circRNA screening criteria: FDR<0.05, | log2FC |>1, obtain 77
Differential expression circRNA.
Further, using the calculating of starBase v3.0,3 differential expression circRNA combination difference expression are obtained
The relationship pair of miRNA, wherein one group is hsa_circ_0020594 and hsa-let-7c-5p.
It is predicted using including these algorithms of RNA22, miRanda, miRDB, miRWalk, PICTAR2 and Targetscan
The target gene for the differential expression hsa-let-7c-5p that hsa_circ_0020594 is combined chooses >=4 algorithms and predicts the target come
Gene, and the target gene of the miRNA for the differential expression having verified that in miRWalk database lookup, the target base of hsa-let-7c-5p
Because IGF2BP2, POLQ, IFI44L, CHEK1, COL4A1, DNA2, ELAVL1, SENP5, EZH2, USP12, TMEM2,
BACE2、ZNF473、GALNT2、AHCTF1、OSBPL3、RPUSD2、C19orf54、HOXC11、CXCL8、GOLT1B、HSPA14、
TAF9B、CCDC93、DARS2、IPO9、UGGT1、POGLUT1、BBX、RAD1、RRM2、DCLRE1B、SLC20A1、AURKA、
TAF5、TAZ、TFDP2、TK1、TRAPPC10、TMPO、ZNF79、ZNF200、PXDN、TSEN34、EIF2S2、CCNF、H2AFV、
CDC25A、SUPT16H、CTPS1、DHX9、DNA2、DNMT1、EZH2、ARL6IP1、ACOT9、GABPB1、TMEM184B、
RBM12B、LYN、MICB、RFWD3、FANCI、PRIM2、IPO9、PSMB2、RRM2、SLC20A1、TAF5、TAZ、TTF1、
ZNF200, TRRAP, CCNF, BAZ1B, CCNB2, NUP155, CEP135 or KIAA0391.It is constructed using Cytoscape3.5.0
Network, the result is shown in Figure 1.
Embodiment 2RT-PCR verifies hsa_circ_0020594 relative expression quantity in cervical squamous cell cancer and cancer beside organism
1. material
The tissue samples for collecting 27 cervical squamous cell carcinoma patients that Gynecological Ward undergos surgery in hospital, by the corresponding cancer of patient
Side tissue is as a control group.Patient's pathological diagnosis is verified through Pathologis.Patient is preoperative not to receive radiotherapy or chemotherapy, and
Without gynecological diseases such as other surgeries, endocrine, metabolic, communicable disease and other ovary and uterus.Aseptic condition obtains fresh
Tissue specimen, physiological saline are distributed into the cryopreservation tube of RNA enzyme after washing away blood, and liquid nitrogen flash freezer is overnight, and -80 DEG C of refrigerators are long-term
It freezes.
2. experimental method
2.1 total tissue RNAs are extracted
(1) each group tissue is shredded on ice, takes appropriate (50-100mg) to be organized in the EP pipe of RNA enzyme and lml is added
The Trizol of pre-cooling, in standing 10min on ice after piping and druming uniformly；
(2) chloroform of 200 μ l pre-cooling is added, acutely shakes after 30sec in standing 15min, 4 DEG C of 14000rpm/min on ice
It is centrifuged 20min；
(3) supernatant is taken out in the new EP pipe for going RNA enzyme (attention avoids touching middle layer), what addition was pre-chilled in equal volume
Isopropanol (about 500 μ l), stands 0.5-1h on ice after mixing, 4 DEG C of 14000rpm/min are centrifuged 20min；
(4) supernatant is abandoned, 75% ethyl alcohol of lml pre-cooling is added, is mixed by inversion, 4 DEG C of 14000rpm/min are centrifuged 20min；
(5) supernatant is abandoned, 75% ethyl alcohol of lml pre-cooling is added, is mixed by inversion, 4 DEG C of 14000rpm/min are centrifuged 20min；
(6) supernatant is abandoned, RNA precipitate is added appropriate DEPC water and sufficiently blows and beats dissolution precipitating after drying in super-clean bench.
RNA quality inspection standard, A260/A280 value is between 1.8 and 2.1.2.0 is optimal, are greater than 2.1, prompt RNA
Degradation is excessive, and less than 1.8 prompts, there are albumen etc. to pollute, the results showed that RNA purity is higher, the pollution such as no protein or DNA.
2.2 design of primers
For the annular closed structure of circRNA, back-to-back primer (divergent primer), GAPDH conduct are designed
Internal reference is sent to Synesis Company's synthesis.
Hsa_circ_0020594 primer:
Upstream primer: 5 '-AGAGGGGTGACAGCGAAAC-3 ' (SEQ ID NO.3)
Downstream primer: 5 '-TGTAGAATCAGTGGGCGTGT-3 ' (SEQ ID NO.4)
Target gene amplification length: 76bp.
2.3 reverse transcription
According to PimeScriptTMRT reagent Kit (Perfect Real Time) RR037A (Takara) specification
Configure reverse transcription reaction system.First by each reagent carry out wink from, be successively added to using pipettor in the EP pipe of RNA enzyme,
It mixes well, is placed in circulator interior be incubated for and RNA is reversed to cDNA, reverse transcription condition is 37 DEG C of 15min, 85 DEG C of 5sec, last 4
DEG C save.
2.4RT-PCR verifies the expression of hsa_circ_0020594 in sample
RT- is configured according to SYBR.Premix Ex TaqTM (Tli RNaseH Plus) RR420A (Takara) specification
PCR reaction system (20 μ l), specifically see the table below.First by each reagent wink from being successively added to the EP of RNA enzyme using pipettor
Guan Zhong is uniformly mixed, and is placed in ABI 7500PCR instrument and is carried out qRT-PCR reaction.
Table 2RT-PCR reaction system
| Component | Volume |
| SYBR Premix Ex Taq(Tli RNaseH Plu) | 10μl |
| PCR Forward Primer | 1μl |
| PCR Reverse Primer | 1μl |
| DNA profiling | 2μl |
| ddH2O | 6μl |
| Filling-in is to 20 μ l |
Reaction condition: denaturation (95 DEG C of 30sec)；Expand 35 circulation (95 DEG C of 5sec；59℃30sec).
2.5 statistical analysis
It is for statistical analysis to experimental data using SPSS17.0 software.Data are indicated with mean value scholar's standard deviation.P is less than
0.05 represents difference with statistical significance, and all experiments are in triplicate.
Real-time quantitative PCR amplification curve entirety collimation is good, shows that the amplification efficiency of each reaction tube is close, amplification curve turns
Point is clear, and the limit is flat and present without raising up, and exponent phase slope is larger, illustrates that amplification efficiency is higher；Sample amplified production is molten
Solution curve be it is unimodal, show that amplified production is unique, be specific amplification；The relative quantification formula of RT-PCR: 2- Δ Ct ×
100%, as the result is shown: hsa_circ_0020594 expression quantity in cancerous tissue is apparently higher than cancer beside organism, and difference has statistics
It learns meaning (P < 0.001), is 7.9 times (concrete outcome is shown in Fig. 2) by cancer, in 27 pairs of samples, 22 pairs of differences between samples expression are bright
Aobvious, expression trend meets expection, and differential expression does not have statistical significance in 4 pairs of samples, and there are also hsa_circ_ in a pair of sample
0020594 expresses slightly above cancerous tissue in cancer beside organism.RT-PCR confirmatory experiment result and data analysis result are almost the same,
It shows that hsa_circ_0020594 is good auxiliary diagnosis molecular marker, may have good clinical value.
Sequence table
<110>Changning district, Shanghai healthcare hospital for women & children
<120>a kind of cervical carcinoma molecular marker and its application
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1364
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
gtgggaacat ccagttgcag gaaaacaagc ttaacacgcc cactgattct acattatggt 60
gagttctata attattttat tatatatcac agtgtaataa tggaaataaa gtgcctaata 120
aatgcaaatg tgcttacatc ttttggccca gctcctacct cccggcagcc tctccaggcc 180
cagaactttc tccagtcagc ctctacagac caagctcatg actcacaatg gcctatttag 240
gcccataccc tacgtcacgg cagcctccgc agatgaggct actgcctcac aacagcctcc 300
acaggcacag ctccatcgtt acaatggcct ctttagaccc agctcctgcc tcccagcctt 360
ctctccaggc cctgaacatt ctcagtaagt tcaggtagct gggactgtag gtatacatga 420
tgatacttgg ctaattttta aattgttttg tagacacggg gtctcacttt gttggccagg 480
ctggtgtcaa actaatggcc tcaagtgacc cttccacccc tgcctcccat cctcgaggca 540
tgtgccacca caaggagcac ttgttcaatt ttctaaaaaa aaaatttcta aagtaaggct 600
gtgggatgat ggcaggaaga taaaagaaaa acagaagaat aagttaaaat gacttattca 660
cacatattct tttgacagca agaagaactt ttagtatgta cattccttac aaacaaacaa 720
aaggcagata aacaatgttg tataggaact tcaacacaca ctgtacaata ttcccacttt 780
gctgacataa gttatggaaa tttcatggtt tacttgagtg tccctaccag tattttgctt 840
ctctgatgat ttttatcaac ttcctcatct gttaacttct ctccaaggta tgtcatgtca 900
cgacatactg ccgctgcacg aacatggcca gtgtcttcct attcaacatg tagaatgctt 960
tcctaatttc tctttttact ctctgtcttt gtgttctgca ttttccttac ttttattgtc 1020
agaaactcca gaaagtcaat cgtactaatt tatcacgatt tgctttatta atttatactt 1080
tgcttatatg gaattttgcc cagcagacct catcacagtt tctaacctgt tttatttttt 1140
attttttatt tttttttgtt ctgagacagg gtctccctct gttgtccaag gctggagtgt 1200
agtagtgcta tcgcagctga ctgcagcctc aaccttccag gctgaagcga tcctcccacc 1260
tcaacctccc acgtggctga gactacaggt gcttgccact atgcccaact aatatttgga 1320
attttcgtat acgtggattc cagaggggtg acagcgaaac gtga 1364
<210> 2
<211> 22
<212> RNA
<213>artificial sequence (Artificial Sequence)
<400> 2
ugagguagua gguuguaugg uu 22
<210> 3
<211> 19
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
agaggggtga cagcgaaac 19
<210> 4
<211> 20
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 4
tgtagaatca gtgggcgtgt 20
Claims (9)
1. the reagent of detection hsa_circ_0020594 is preparing the application in diagnosis of cervical cancer preparation, wherein hsa_circ_
0020594 sequence is SEQ ID NO.1.
2. application according to claim 1, which is characterized in that reagent uses sequencing technologies, nucleic acid hybridization technique or nucleic acid
Amplification technique detects the expression of hsa_circ_0020594 in sample.
3. application according to claim 2, which is characterized in that nucleic acid hybridization technique includes but is not limited in situ hybridization, micro-
Array or Northern hybridization.
4. application according to claim 1, which is characterized in that use high throughput sequencing technologies, probe hybridization technique, gene
The expression of hsa_circ_0020594 in chip technology or fluorescent quantitative PCR technique detection sample.
5. application according to claim 1, which is characterized in that reagent contains the probe hybridized with hsa_circ_0020594
Or the specific primer of amplification hsa_circ_0020594.
6. application according to claim 5, which is characterized in that primer sequence is SEQ ID NO.3 and SEQ ID NO.4.
7. application according to claim 1, which is characterized in that sample is cervical cancer tissues or peripheral blood.
8. application according to claim 1, which is characterized in that cervical carcinoma is cervical squamous cell carcinoma.
9. a kind of cervical carcinoma detects PCR kit for fluorescence quantitative, which is characterized in that kit is using special upstream primer under
Swim the expression of primer detection hsa_circ_0020594.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910100360.1A CN109666743B (en) | 2019-01-31 | 2019-01-31 | A kind of cervical carcinoma molecular marker and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910100360.1A CN109666743B (en) | 2019-01-31 | 2019-01-31 | A kind of cervical carcinoma molecular marker and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109666743A CN109666743A (en) | 2019-04-23 |
| CN109666743B true CN109666743B (en) | 2019-09-24 |
Family
ID=66151120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910100360.1A Active CN109666743B (en) | 2019-01-31 | 2019-01-31 | A kind of cervical carcinoma molecular marker and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109666743B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110747276B (en) * | 2019-11-22 | 2020-06-30 | 山东大学齐鲁医院 | Application of BACE2 as glioma prognosis/diagnosis/treatment marker |
| CN113528662B (en) * | 2021-05-21 | 2022-10-28 | 山西医科大学第二医院 | CircRNA marker, specific primer pair, kit and application for detecting cervical cancer |
| CN113718035B (en) * | 2021-09-30 | 2023-03-28 | 安徽同科生物科技有限公司 | Application of circular RNA hsa _ circ _0003552 and kit for detecting circular RNA hsa _ circ _0003552 |
| CN114255823A (en) * | 2021-12-08 | 2022-03-29 | 四川省医学科学院·四川省人民医院 | Construction method and application of retinal degenerative disease model |
| CN115466793B (en) * | 2022-09-26 | 2023-09-01 | 山东大学 | Application of ACOT9 gene detection reagent in preparation of gastric cancer detection kit and gastric cancer detection kit |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108893540B (en) * | 2018-06-08 | 2021-11-19 | 中国农业科学院北京畜牧兽医研究所 | CircRNA _14707 and application thereof in molecular assisted breeding |
-
2019
- 2019-01-31 CN CN201910100360.1A patent/CN109666743B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109666743A (en) | 2019-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109666743B (en) | A kind of cervical carcinoma molecular marker and its application | |
| CN109666744B (en) | CircRNA and its preparing the application in diagnosis of cervical cancer reagent | |
| JP2010510769A (en) | Methods and compositions for diagnosis of esophageal cancer and prognosis and improvement of patient survival | |
| KR102029775B1 (en) | Biomarkers for diagnosis of Non-muscle invasive bladder cancer and uses thereof | |
| CN108753969B (en) | Application of long-chain non-coding RNA in hepatocellular carcinoma diagnosis and treatment | |
| EP3122905B1 (en) | Circulating micrornas as biomarkers for endometriosis | |
| CN107674916B (en) | Application of circular RNA in colorectal cancer biomarker | |
| CN108504658B (en) | Application of LINC01836 in preparation of gastric cancer diagnosis products and treatment medicines | |
| CN107519193B (en) | Molecular diagnostic marker for early stage esophageal squamous carcinoma and application thereof | |
| CN108949969B (en) | Application of long-chain non-coding RNA in colorectal cancer | |
| CN110628913B (en) | lncRNA marker related to breast cancer | |
| CN108624693B (en) | MiR-577 is preparing the application in diagnosis of nephropathy marker | |
| CN109913458A (en) | CircRNA and its application in detection hypoxic-ischemic brain damage | |
| CN108220446B (en) | Application of LINC01356 as molecular marker in gastric cancer | |
| CN109022583A (en) | Hsa_circ_0021977 is preparing the application on Diagnosis of Breast cancer product | |
| CN106244688B (en) | A kind of marker for assessing adenocarcinoma of colon risk | |
| CN107058579A (en) | Adenocarcinoma of lung related miRNA, composition and its application | |
| CN108660211B (en) | Hepatocellular carcinoma-related biomarker LINC01549 and application thereof | |
| CN108707672B (en) | Application of DUXAP8 in diagnosis and treatment of hepatocellular carcinoma | |
| CN110923324A (en) | Breast cancer miRNA marker and application thereof | |
| CN107227362B (en) | Gene related to liver cancer and application thereof | |
| WO2022057193A1 (en) | Long-chain non-coding rna and use of inhibitor thereof | |
| CN110592219B (en) | lncRNA diagnosis and treatment marker for breast cancer | |
| CN108624689B (en) | Application of biomarker LINC01451 | |
| WO2016160882A1 (en) | Methods for diagnosing and treating colorectal cancer using mirna549a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |